FDA Performance Tracker
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
![](/-/media/editorial/pink-sheet/2024/06/ps2406_dry_land_2177533861_1200.jpg?rev=60b6a6bf3b4d47e9a6f704ab8cd4934e&w=350&hash=9A1AAC200C511A0E64B389135DE4AB50)
US FDA’s Dry July? Few Goal Dates Portend Quiet Month For Approvals
Sun’s deuruxolitinib and Novo Nordisk’s insulin icodec stand out as new molecular entities among the small cluster of US FDA user fee goal dates in July.
![](/-/media/editorial/pink-sheet/2024/05/ps2405_grill-and-grass_682186153.jpg?rev=c9a547d004cc4b63a1bcdde65ab301f3&w=350&hash=38F7E5B7EF0EB8E86A3FA0863E459B96)
US FDA’s June Approvals Forecast: Nearly 30 Goal Dates Suggest Hot Start To Summer
June goal dates include RSV and pneumococcal vaccines, two COPD therapies, Rocket and Sarepta gene therapies, and lots of oncology.
![](/-/media/editorial/pink-sheet/2024/05/ps2405_statistics_analysis_419539486_1200.jpg?rev=18fece44114c4e5a8c811b768c63875c&w=350&hash=45FAF1C0B5A55C6C33D160E059A62732)
US FDA’s Novel Approvals Peak Near Year-End, Analysis Of Last Decade Suggests
The Center for Drug Evaluation and Research’s novel approvals concentrated in August, November, and December, while January and June were the slowest months, according to a Pink Sheet analysis of 2014-2023 data.
![](/-/media/editorial/pink-sheet/00_regular-column-images/keepingtrack_1200x675.jpg?rev=4276419b6cca4acfacf8abd02c216d94&w=350&hash=A66D2B9AF6430E2748C184C04E0404F2)
Keeping Track Of AdComms: US FDA Puts Donanemab On Schedule, Delays COVID-19 Meeting
Newly announced US FDA advisory committee meetings on Lilly’s Alzheimer’s antibody, Lykos’ pioneering psychedelic therapy for PTSD relieve drought in non-oncology AdComms as the 2024-‘25 COVID vaccine strain selection meeting is postponed.
![](/-/media/editorial/pink-sheet/2024/05/ps2405_rsv_test_2358869961_1200.jpg?rev=ead987ce95c947ab90dfc7cc148cc3c9&w=350&hash=14AD250D67E1DFE8461971F75E3B599F)
US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics
Five novel agents are among the user fee goal dates coming up in May 2024.
![](/-/media/editorial/pink-sheet/00_regular-column-images/keepingtrack_1200x675.jpg?rev=4276419b6cca4acfacf8abd02c216d94&w=350&hash=A66D2B9AF6430E2748C184C04E0404F2)
Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy
The US FDA approved Day One’s pediatric brain cancer drug Ojemda, ImmunityBio’s bladder cancer immunotherapy Anktiva, an uncomplicated UTI claim for Utility Therapeutics’ Pivya, which has a long history in Europe, and Pfizer’s hemophilia B gene therapy Beqvez.
![](/-/media/editorial/pink-sheet/00_regular-column-images/keepingtrack_1200x675.jpg?rev=4276419b6cca4acfacf8abd02c216d94&w=350&hash=A66D2B9AF6430E2748C184C04E0404F2)
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
![](/-/media/editorial/pink-sheet/2024/04/ps2404_bristol-building_2194452323-1200.jpg?rev=372a523dd4b54d9885f668edfb0c4f79&w=350&hash=FAEE7097AF2F2DAFA447BDE47D5EFDFD)
Abecma Approval In Earlier Myeloma Carries Caution On Early Death Data
Labeling describes early death imbalance that delayed approval of Bristol Myers Squibb’s CAR-T therapy for more than three months after its user fee goal, but does not add to boxed warning; J&J’s Carvykti is due for imminent US FDA action on its own early-stage myeloma bid.
![](/-/media/editorial/pink-sheet/00_regular-column-images/keepingtrack_1200x675.jpg?rev=4276419b6cca4acfacf8abd02c216d94&w=350&hash=A66D2B9AF6430E2748C184C04E0404F2)
Keeping Track: Cardio-Renal Drugs At Heart Of US FDA’s March Approval Binge
Seven novel agents approved in March include one accelerated approval, two rare pediatric disease priority review vouchers, two breakthrough therapy designations and one regenerative medicine advance therapy designation.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.